GC
KYNB

Globeflex Capital’s Kyntra Bio KYNB Stock Holding History

Globeflex Capital’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,345
Closed -$720K – 491
2016
Q4 		$720K Hold
1,345
– – 0.18% 213
2016
Q3 		$696K Hold
1,345
– – 0.17% 209
2016
Q2 		$552K Hold
1,345
– – 0.15% 222
2016
Q1 		$716K Buy
1,345
+1,193
+785% +$594K 0.19% 184
2015
Q4 		$116K Sell
152
-884
-85% -$587K 0.03% 327
2015
Q3 		$568K Buy
+1,036
New +$628K 0.12% 272

Other funds holding KYNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Globeflex Capital's KYNB Position: Q1 2017 in Review

Globeflex Capital sold out of Kyntra Bio (KYNB) in Q1 2017, closing a stake of 1,345 shares — an estimated $720K sold.

Globeflex Capital first reported a position in KYNB in Q3 2015 and held it in 6 quarters. The position peaked at $720K in Q4 2016. 144 funds tracked by Wall St. Rank hold KYNB as of Q1 2017.

  • Globeflex Capital reported no remaining Kyntra Bio position as of Q1 2017 after selling out during the quarter.
  • Globeflex Capital sold 1,345 Kyntra Bio shares in Q1 2017, an estimated $720K.
  • Globeflex Capital first reported a position in Kyntra Bio in Q3 2015 and held it in 6 quarters.
  • Globeflex Capital's Kyntra Bio position peaked at $720K in Q4 2016.
  • 144 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2017.

Based on Globeflex Capital's 13F filing for Q1 2017, filed 12 May 2017.